SCHEMBL22415211

SCHEMBL22415211

CCN/N=C(\N)c1ccc(Cl)nc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 0.46
▸ NAPRT Q6XQN6 1/20 0.42
▸ RAB9A P51151 6/20 0.42
▸ MAPT P10636 3/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ADRA2A P08913 2/20 0.40
▸ ADRA2B P18089 2/20 0.40
▸ ADRA2C P18825 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19719710 0.80 NAPRT (0.47) DGAT1NAPRTRAB9AL3MBTL1MEN1
SCHEMBL14445416 0.80 DGAT1 (0.51) DGAT1NAPRTRAB9AMAPTL3MBTL1
SCHEMBL13342190 0.74 NAPRT (0.52) DGAT1NAPRTRAB9AMAPTL3MBTL1
SCHEMBL1726660 0.74 NAPRT (0.52) DGAT1NAPRTRAB9AMAPTL3MBTL1
SCHEMBL1726659 0.74 NAPRT (0.52) DGAT1NAPRTRAB9AMAPTL3MBTL1
SCHEMBL23845464 0.74 NAPRT (0.52) DGAT1NAPRTRAB9AMAPTL3MBTL1
SCHEMBL30515503 0.74 NAPRT (0.52) DGAT1NAPRTRAB9AMAPTL3MBTL1
SCHEMBL17778492 0.74 NAPRT (0.52) DGAT1NAPRTRAB9AMAPTL3MBTL1
SCHEMBL22415213 0.74 DGAT1 (0.45) DGAT1NAPRTRAB9AMAPTL3MBTL1
SCHEMBL23212893 0.73 KDM4E (0.47) NAPRTRAB9AMAPTL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3257851-B1 SALT FORM AND CRYSTAL FORM OF 1,2,5 THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE JIANGSU KANION PHARMACEUTICAL CO LTD (CN) 2020-09-09 — — EP disclosed
Send feedback